These changes are a reflection of your bodys metabolic health rather than a direct result of GLP-1 medication
A comprehensive narrative review published in Biology synthesized 78 studies across five mechanistic domains and identified a compelling pathway
Phentermine, an FDA-approved appetite suppressant since 1959, works through central nervous system stimulation, while tirzepatide (Zepbound, Mounjaro), approved in 2023 for obesity, operates through dual GIP/GLP-1 receptor pathways
Parallel evaluation of immune cell dynamics, such as the frequency of regulatory T cells and anti-inflammatory macrophages, is also crucial, particularly as preclinical data suggest PSYs may enhance these immunoregulatory responses, though this remains to be validated in humans
These advancements are designed to improve flexibility for providers while maintaining safety and compliance standards